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Joshi AD, Barabutis N, Birmpas C, Dimitropoulou C, Thangjam G,
Cherian-Shaw M, Dennison J, Catravas JD. Histone deacetylase inhibi-
tors prevent pulmonary endothelial hyper-permeability and acute lung injury
by regulating heat shock protein 90 function. Am J Physiol Lung Cell Mol
Physiol 309: L1410–L1419, 2015. First published October 23, 2015;
doi:10.1152/ajplung.00180.2015.—Transendothelial hyperpermeability
caused by numerous agonists is dependent on heat shock protein 90
(Hsp90) and leads to endothelial barrier dysfunction (EBD). Inhibition
of Hsp90 protects and restores transendothelial permeability. Hyper-
acetylation of Hsp90, as by inhibitors of histone deacetylase (HDAC),
suppresses its chaperone function and mimics the effects of Hsp90
inhibitors. In this study we assessed the role of HDAC in mediating
lipopolysaccharide (LPS)-induced transendothelial hyperpermeability
and acute lung injury (ALI). We demonstrate that HDAC inhibition
protects against LPS-mediated EBD. Inhibition of multiple HDAC by
the general inhibitors panobinostat or trichostatin provided protection
against LPS-induced transendothelial hyperpermeability, acetylated
and suppressed Hsp90 chaperone function, and attenuated RhoA
activity and signaling crucial to endothelial barrier function. Treat-
ment with the HDAC3-selective inhibitor RGFP-966 or the HDAC6-
selective inhibitor tubastatin A provided partial protection against
LPS-mediated transendothelial hyperpermeability. Similarly, knock
down of HDAC3 and HDAC6 by specific small-interfering RNAs
provided significant protection against LPS-induced EBD. Further-
more, combined pharmacological inhibition of both HDAC3 and -6
attenuated the inflammation, capillary permeability, and structural
abnormalities associated with LPS-induced ALI in mice. Together
these data indicate that HDAC mediate increased transendothelial
hyperpermeability caused by LPS and that inhibition of HDAC
protects against LPS-mediated EBD and ALI by suppressing Hsp90-
dependent RhoA activity and signaling.
histone deacetylases; endothelium; barrier function; r RhoA; myosin
light chain; lipopolysaccharide; inflammation; acute lung injury
LIPOPOLYSACCHARIDE (LPS), a major component of the bacte-
rial wall cell membrane, is released in the bloodstream
during infection after bacteria are lysed by white blood cells
(8, 44). LPS binds to the Toll-like receptor 4 receptor
complex on endothelial cells and induces multiple signaling
pathways that lead to the production and release of proin-
flammatory cytokines and endothelial barrier dysfunction
(EBD) (19, 45, 54). Inflammation and EBD are the primary
causes of acute lung injury (ALI) and acute respiratory
distress syndrome (ARDS) (3, 18, 44, 46).
The ATP-dependent molecular chaperone heat shock protein
90 (Hsp90) plays a central role in LPS-mediated EBD (4, 16).
LPS potentiates Hsp90 chaperone function by inducing
pp60Src-dependent Y-300 phosphorylation of Hsp90 (9). Inhib-
itors of Hsp90 block LPS-induced Y-300 phosphorylation in
cultured human lung microvascular endothelial cells (HLM-
VEC) (9) and prolong survival, attenuate inflammation, and
reduce lung injury in a murine model of LPS-induced ALI/
ARDS (15). Long-term treatment (8 h) with small molecule
inhibitors of Hsp90 causes destabilization and ubiquitin-medi-
ated degradation of numerous client proteins, such as protein
kinase B (Akt) and pp60Src (10, 21, 24, 55). However, even
short-term treatment (4 h) with Hsp90 inhibitors attenuates
LPS-induced RhoA activation and signaling and protects
against LPS-mediated EBD in HLMVEC (31).
Histone deacetylases (HDAC) remove acetyl groups from
the ε-amino group of lysine residues in numerous histone and
nonhistone proteins such as Hsp90 (11, 61). In humans, there
are 18 characterized HDAC distributed into four classes.
HDAC3, a class I HDAC, is primarily a nuclear protein that
shuttles to the cytoplasm when phosphorylated (53, 61), local-
izes to the plasma membrane, and is a substrate of Src (39).
Conversely, HDAC6 is primarily a cytoplasmic protein and a
unique member of class II HDAC (12). HDAC6 acetylation
results in nuclear translocation and regulation of gene expres-
sion (38). HDAC inhibitors exhibit anti-inflammatory proper-
ties by suppressing proinflammatory cytokine production (6,
22, 30, 59) and reducing disease severity in animal models of
inflammatory and autoimmune disease (6, 43, 48). In endothe-
lial cells, HDAC inhibitors suppress thrombin-induced EBD
(49). Importantly, inhibition of HDAC induces Hsp90 acety-
lation at lysine-294 and suppresses its chaperone function,
thereby mimicking the effect of Hsp90 inhibitor (50). Both
HDAC3 and -6 interact with and deacetylate Hsp90, and
inhibition of HDAC3 and -6 hyperacetylates Hsp90 (29, 35,
50), suggesting a possible role of these two HDAC in EBD.
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In this study, we demonstrate that inhibition of HDAC
protects against LPS-mediated EBD. Particularly, we show that
selective pharmacological or genetic inhibition of HDAC3
and/or HDAC6 provides partial protection against LPS-medi-
ated endothelial hyperpermeability. Finally, we demonstrate
that HDAC acts upstream of Hsp90 and that inhibition of
HDAC acetylates Hsp90, suppressing its chaperone function.
Together, our data suggest a central role for basal and induced
HDAC activity in LPS-mediated endothelial hyperpermeabil-
ity and EBD.
MATERIALS AND METHODS
Antibodies and reagents. Antibodies against acetyl-lysine, phos-
pho-Akt, Akt, myosin light chain (MLC), and di-phospho-MLC were
purchased from Cell Signaling. Anti-Hsp90 antibodies were pur-
chased from BD Biosciences (610418) and Enzo Life Sciences (ADI-
SPA-840). Anti--actin antibody was purchased from Sigma-Aldrich
(St. Louis, MO), as were antibodies against S424-HDAC3, HDAC3,
and HDAC6. PY99 antibody was purchased from Santa Cruz Bio-
technologies (Santa Cruz, CA). The HDAC inhibitors panobinostat
(Pan) and trichostatin (TSA) and the Hsp90 inhibitor AUY-922
(S1069) were obtained from Selleck Chemicals. Selective HDAC3
inhibitor RGFP-966 and selective HDAC6 inhibitor tubastatin were
purchased from Selleck Chemicals. HDAC3 (sc-35538), HDAC6
(sc-35544), and control small-interfering RNA (siRNA, sc-37007)
were purchased from Santa Cruz Biotechnology. Oligofectamine was
obtained from Fisher Scientific (Pittsburg, PA).
Cell culture. HLMVEC were isolated and cultured in-house as
described previously (14).
HDAC activity assay. HDAC activity was measured using the
fluor-de-lys HDAC activity assay kit in accordance with the manu-
facturer’s instructions (Enzo Life Sciences). After treatment, HLM-
VEC were lysed, and cell lysates were used to measure HDAC
activity. Results were normalized to protein levels measured using the
bicinchonic acid assay reagent (Bio-Rad).
Transendothelial permeability. Transendothelial resistance (TER)
measurements were performed as described previously (16). Briefly,
60,000 cells were seeded on each well of a 8W10E ECIS array.
After 24 h, the media were changed, and treatments began at 48 h
when the resistance was stable between 900 and 1,200  at a
frequency of 4,000 Hz, and the capacitance was between 22 and 29
nF. Each experiment was performed at least in triplicate and repeated
at least three times (n  3). Resistance was measured using the ECIS
model Z	 and normalized to each well’s value at time  0 h.
RhoA activity assay. RhoA activity was determined using a Rho
G-LISA assay kit in accordance with the manufacturer’s instructions
(Cytoskeleton) using HLMVEC cell lysates. Results were normalized
to protein levels, measured by the Precision Red protein assay reagent.
Cell fractionation. Cytoplasmic and nuclear extract were prepared
using the nuclear kit from Active Motif.
Western blotting and immunoprecipitation. Western blot analyses
and immunoprecipitation experiments were performed as described
previously (9, 31). Densitometry was performed using Image Studio
version 3.1 from Licor and plotted as fold change from vehicle.
Animal experiments. Mice (C57/6; Harlan) were injected intraperi-
toneally with 10 mg/kg each of RGFP-966 and tubastatin. After 24 h,
the animals were anesthetized (ketamine/xylaxine), and 1.5 mg/kg
LPS were instilled through the trachea. Later (24 h), the animals were
similarly anesthetized, and bronchoalveolar lavage (BAL) was per-
formed with 1 ml saline. BAL fluid (BALF) was collected and used
for measurements of cellularity and protein concentration.
siRNA transfection. siRNAs against human HDAC3 and HDAC6
were used to knock down the expression of the respective proteins in
HLMVEC. siRNA, which does not lead to the degradation of any
known cellular mRNA, was used as control. siRNAs were diluted in
Opti-MEM I Reduced Serum Medium, and oligofectamine was di-
luted in an equal volume of Opti-MEM I and incubated for 30 min at
room temperature. The oligomer-Lipofectamine complexes were
added to cells, which were cultured in media free of antibiotics. The
medium was changed 8 h after transfection. Cells were incubated at
37°C in an atmosphere of 5% CO2 and 95% air for 48 h after
transfection and then assayed by Western blotting or used in ECIS
experiments.
Statistical analyses. Data are presented as mean values 
 SE.
Comparisons among groups were performed using either paired t-test,
one-way or two-way ANOVA with Bonferroni posttest, as appropri-
ate. Differences were considered significant at P  0.05, and n
represents the number of experimental repeats.
RESULTS
HLMVEC grown to confluence were exposed to either PBS
or LPS [0.2, 1, or 5 endotoxin units (EU)/ml] for 2 h. After cell
lysis, HDAC activity was measured as described in MATERIALS
AND METHODS. Compared with PBS-treated cells, LPS-exposed
cells exhibited a modest but consistent and significant increase
in HDAC activity in whole cell lysates (111 
 3, 122 
 3, and
117 
 2%, respectively, for 0.2, 1, and 5 EU/ml LPS),
indicating that LPS signaling activates cellular HDAC func-
tion. The LPS-induced HDAC activity increased as early as 1
h (122 
 2%) and remained elevated at 2 h (130 
 7%).
Because HDAC are found in both the cytoplasm and the
nucleus, we isolated the cytoplasmic and the nuclear extract

















































Fig. 1. Histone deacetylase (HDAC) inhibition protects against the lipopoly-
saccharide (LPS)-mediated decrease in transendothelial resistance (TER).
Human lung microvascular endothelial cells (HLMVEC) were grown to
confluence on ECIS arrays (8W10E). Once a constant resistance was
attained, the cells were treated with either vehicle (0.1% DMSO) or 1 M
panobinostat (Pan; A) or 2 M trichostatin (TSA; B) for 2 h. LPS [1 endotoxin
unit (EU)/ml] was then added as indicated, and TER values were measured
using ECIS Z	. Normalized resistance was calculated and plotted as a function
of time. P  0.01 from vehicle (*) and LPS (#); n  4 experiments.
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tivity in the cytoplasm (100 
 4, 112 
 1, and 115 
 1%) and
nucleus (100 
 1, 118 
 1, and 115 
 1%) for 0.2, 1, and 5
h, respectively.
HDAC inhibition protects against the LPS-mediated de-
crease in TER. Pan-HDAC inhibitors target multiple class I
and class II HDAC and have a broad effect on HDAC activity
and function. Therefore, we hypothesized that treatment with
pan-HDAC inhibitors would attenuate LPS-mediated endothe-
lial hyperpermeability. ECIS arrays were used to measure TER
across the endothelial cell monolayer. HLMVEC were grown
on gold electrode arrays, and TER values were monitored
continuously until a constant value was attained, suggesting a
confluent monolayer. Cells were then exposed to vehicle or the
HDAC inhibitor Pan (1 M) or TSA (2 M) for 2 h followed
by PBS or LPS (1 EU/ml). These concentrations are higher
than those frequently used in tumor cells because it is well
known that nontumor normal cells are less responsive to
HDAC inhibitors (56). LPS decreased TER values, suggesting
an increase in monolayer permeability. Pretreatment with ei-
ther Pan (Fig. 1A) or TSA (Fig. 1B) prevented the LPS-
mediated decrease in HLMVEC monolayer TER, suggesting
that HDAC activity and function is necessary for LPS-induced
endothelial hyperpermeability.
HDAC inhibition attenuates LPS-induced Hsp90 activation
and chaperone function. Hsp90 plays a central role in LPS-
mediated EBD. Therefore, we hypothesized that the HDAC
effects on EBD may involve Hsp90. Confluent HLMVEC were






























































































VEH      LPS     Pan  Pan+LPS
Fig. 2. HDAC inhibition attenuates LPS-induced heat shock pro-
tein 90 (Hsp90) chaperone function. A: confluent monolayers were
treated with vehicle or 2 M AUY-922 (Hsp90 inhibitor) for 4 h
followed by exposure to LPS (1 EU/ml) for 2 h. Cells were then
lysed, and HDAC activity was measured using the Flour-de-lys
HDAC activity assay. *P  0.05 from vehicle or AUY. B:
confluent monolayers were treated with vehicle, LPS (1 EU/ml), 1
M TSA for 2 h followed by exposure to LPS for 2 h, or 1 M Pan
for 2 h followed by exposure to LPS for 2 h. Cells were lysed, and
Hsp90 was immunoprecipitated and immunoblotted for phoshoty-
rosine and Hsp90. P  0.05 from vehicle (*) and LPS (#); n  3.
C: HLMVEC were treated with vehicle (VEH) or 1 M Pan; cells
were then lysed, and Hsp90 was immunoprecipitated and immu-
noblotted for acetyl-lysine and Hsp90. *P  0.05; n  3. D:
HLMVEC were treated with vehicle, LPS (1 EU/ml), 1 M
panobinostat, or 1 M panobinostat for 2 h followed by exposure
to LPS (1 EU/ml) for 2 h. Cells were then lysed and immunoblot-
ted for phosho-protein kinase B (Akt, S473) and Akt. Densitomet-
ric analysis was carried out, and the ratio of pAkt to Akt was





























Fig. 3. HDAC inhibition suppresses LPS-induced RhoA activity and signaling. A: confluent HLMVEC were treated with vehicle, LPS (1 EU/ml), 1 M Pan,
or Pan for 2 h followed by exposure to LPS for 2 h (Pan  LPS). Cells were then lysed, and RhoA activity was measured using the G-LISA RhoA activation
assay. P  0.05 from vehicle (*) and LPS (#); n  5. B: HLMVEC were grown in 6-well plates. Confluent monolayers were treated with vehicle, LPS (1 EU/ml),
1 M panobinostat, or panobinostat for 2 h followed by exposure to LPS for 2 h. Cells were then lysed and immunoblotted with antibodies against pp-myosn
light chain (MLC)2, MLC2, and -actin. *P  0.01 vs. vehicle. *P  0.05 from LPS. C: cells were treated as in B except instead of Pan 1 M TSA was added.
P  0.05 from vehicle (*) and LPS (#); n  5.
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922 followed by exposure to LPS (1 EU/ml). At the end of
treatment, cells were lysed, and total cellular HDAC activity
was measured, as described in MATERIALS AND METHODS. LPS
alone increased HDAC activity. AUY-922 did not affect either
the basal or the LPS-induced HDAC activity (Fig. 2A), sug-
gesting that Hsp90 functions downstream of HDAC. To prove
this, we then examined the effects of HDAC inhibitors on
Hsp90 activation and function.
LPS induces Hsp90-Y-300 phosphorylation via pp60Src to
activate Hsp90 and potentiate its chaperone function. If
HDACs act upstream of Hsp90 then inhibition of HDAC
function would affect LPS-induced Hsp90-Y-300 phosphor-
ylation. To test this, we pretreated HLMVEC with Pan or
TSA followed by exposure to LPS. Both Pan and TSA
completely blocked LPS-induced Y-300 phosphorylation of
Hsp90 (Fig. 2B).
Acetylation of Hsp90 suppresses its chaperone function.
Therefore, we determined whether HDAC inhibition acetylates
Hsp90 in HLMVEC. Treatment with Pan for 2 h increased
Hsp90 acetylation (Fig. 2C). Furthermore, Pan completely
abolished the LPS-induced and Hsp90-dependent phosphory-
lation of Akt, an Hsp90 client protein (Fig. 2D). Taken to-
gether, the data in Fig. 2 suggest that HDAC inhibition pre-
vents Hsp90 activation and suppresses its chaperone function.
HDAC inhibition suppresses LPS-mediated RhoA activity
and signaling. The RhoA-Rho kinase (ROCK) pathway is an
important mediator of the cytoskeletal changes associated with
HLMVEC exposure to LPS (13, 25). ROCK inhibitors block
LPS-induced MLC phosphorylation and protect against LPS-
induced EBD (23, 37). Recently, we reported that Hsp90
inhibition attenuates LPS-induced RhoA activation and MLC
phosphorylation in HLMVEC (31). Therefore, we hypothe-
sized that HDAC inhibition would block the LPS-triggered and
Hsp90-dependent RhoA-mediated signaling. LPS increased
RhoA activity, and Pan pretreatment for 2 h attenuated this
LPS-induced RhoA activity (Fig. 3A). Furthermore, LPS in-
duced diphosphorylation of MLC2 in HLMVEC, and this
induction was completely blocked by either Pan or TSA (Fig.
3, B and C). These data suggest that HDAC inhibition blocks
RhoA activity and signaling, most likely by attenuating Hsp90
chaperone function.
HDAC3 is involved in LPS-induced EBD. HDAC3 and
HDAC6 have been reported to interact with Hsp90. Therefore,




































































































































Fig. 4. HDAC3 inhibition protects from LPS-induced
endothelial barrier dysfunction (EBD). A: HLMVEC
were grown in 100-mm dishes. When confluent, the
cells were treated with either PBS or LPS (1 EU/ml) for
2 h. Cells were then lysed, HDAC3 was immunopre-
cipitated, and HDAC activity was measured using the
Flour-de-lys HDAC activity assay. *P  0.05; n  4.
B: HLMVEC were treated as above. Cells were lysed,
and HDAC3 was immunoprecipitated and then immu-
noblotted for phospho (p)-serine-424 and HDAC3. *P 
0.05; n  3. C and D: HLMVEC were grown in
100-mm dishes. When confluent, the cells were treated
with the indicated concentrations of the HDAC3-selec-
tive inhibitor RGFP-966 for 2 h, and total HDAC (C)
and HDAC3 (D) activity was measured, as described
previously. *P  0.05 from vehicle; n  4. E: HLM-
VEC were grown to confluence on ECIS arrays
(8W10E). Once a constant resistance was attained,
the cells were treated with either vehicle (0.1% DMSO)
or 5 M RGFP-966 (RGF) for 2 h. LPS (1 EU/ml) was
then added as indicated, and TER values were mea-
sured using an ECIS Z	. *P  0.05 from vehicle. #P 
0.01 from LPS.
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LPS-induced EBD. Confluent HLMVEC were exposed to
vehicle or LPS (1 EU/ml) for 2 h and lysed, HDAC3 was
immunoprecipitated, and HDAC activity was measured as
described in MATERIALS AND METHODS. LPS significantly in-
creased HDAC3 activity above basal levels observed in vehi-
cle-treated cells (Fig. 4A). Immunoprecipitated HDAC3 exhib-
ited an LPS-induced increase in S424 phosphorylation (Fig.
4B), which is consistent with studies showing increased activ-
ity of S424-phosphorylated HDAC3 (62).
We then determined whether inhibition of HDAC3 blocks
the LPS-mediated decrease in TER. To that end, we employed
the HDAC3-selective inhibitor RGFP-966. Pretreatment with
RGFP-966, at a concentration similar to those reported in the
literature without apparent toxic effects (57), moderately but
significantly reduced total HDAC activity (Fig. 4C) in a con-
centration-dependent manner but nearly abolished HDAC3
activity, also in a concentration-dependent manner (Fig. 4D).
Importantly, pretreatment with RGFP-966 significantly atten-
uated the LPS-induced decrease in TER (Fig. 4E). These data
suggest that HDAC3 plays a significant role in LPS-mediated
EBD.
HDAC6 inhibition attenuates the LPS-mediated EBD.
HDAC6 interacts with and regulates Hsp90 chaperone function
(7, 50). Inhibition of HDAC6 blocks endothelial hyperperme-
ability induced by thrombin (49). Therefore, we hypothesized
that LPS modulates HDAC6 activity and that inhibition of
HDAC6 may prevent the LPS-induced endothelial hyperper-
meability. Confluent HLMVEC were exposed to vehicle or
LPS (1 EU/ml) for 1 or 2 h and lysed, HDAC6 was immuno-
precipitated, and HDAC activity was measured as described in
MATERIALS AND METHODS. LPS did not affect basal HDAC6
activity (Fig. 6A). Similarly, LPS did not affect the expression
of either HDAC3 or HDAC6 proteins (data not shown). We
then determined whether HDAC6 is involved in the LPS-
















































































Fig. 5. HDAC6 inhibition protects against LPS-in-
duced EBD. A: HLMVEC were grown in 100-mm
dishes. When confluent, the cells were treated with
either PBS or LPS (1 EU/ml) for 2 h. Cells were then
lysed, HDAC6 was immunoprecipitated, and HDAC
activity was measured using the Flour-de-lys HDAC
activity assay. B and C: HLMVEC were grown in
100-mm dishes. When confluent, the cells were
treated with the indicated concentrations of the
HDAC6-selective inhibitor tubastatin for 2 h, and
total HDAC (B) and HDAC6 (C) activity were mea-
sured, as described previously. *P  0.05 from vehi-
cle; n  4. D: HLMVEC were grown to confluence on
ECIS arrays (8W10E). Once a constant resistance
was attained, the cells were treated with either vehicle
(0.1% DMSO) or 5 M tubastatin (Tub) for 2 h. LPS
(1 EU/ml) was then added as indicated, and TER
values were measured using ECIS Z	. *P  0.01














































Fig. 6. Combined inhibition of HDAC3 and -6 prevents MLC phosphorylation
and abrogates Hsp90 chaperone function. A: HLMVEC were grown in 6-well
plates. Confluent monolayers were treated with vehicle, LPS, 5 M RGFP-
966  5 M tubastatin (RT), or RT for 2 h followed by exposure to LPS (1
EU/ml) for 2 h. Cells were then lysed and immunoblotted with antibodies
against ppMLC2 and MLC2. P  0.05 from vehicle (*) and LPS (#); n  4.
B: cells were treated as in A and immunoblotted with antibodies against pAkt
and Akt. P  0.05 from vehicle (*) and LPS (#); n  4.
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selective inhibitor tubastatin A for 2 h and at a concentration
similar to those reported in the literature without apparent toxic
effects (17) moderately but significantly reduced total HDAC
activity (Fig. 5B) in a concentration-dependent manner but
nearly abolished HDAC6 activity, also in a concentration-
dependent manner (Fig. 5C). Furthermore, pretreatment with
tubastatin A blocked the LPS-induced decrease in TER (Fig.
5D). These data suggest that, even though HDAC6 activity is
not affected by LPS, HDAC6 plays an important part in
LPS-mediated EBD.
Combined inhibition of HDAC3 and -6 attenuates LPS-
mediated EBD. As shown in Figs. 4 and 5, selective inhibi-
tion of either HDAC3 or HDAC6 provides partial but
significant protection against LPS-mediated EBD. There-
fore, we investigated the effect of combined inhibition of
HDAC3 and -6. HLMVEC were exposed to 5 M each of
RGFP-966 and tubastatin for 2 h, followed by LPS (1
EU/ml). This treatment essentially abolished the LPS-in-
duced MLC2 phosphorylation (Fig. 6A) and Hsp90 chaper-
one function, as reflected in Akt phosphorylation (Fig. 6B).
To further assess the combined role of HDAC3 and -6 in
LPS-mediated EBD, HLMVEC were transfected with
siRNAs against HDAC3 and -6. The siRNA produced
80% inhibition of HDAC3 and HDAC6 expression (Fig. 7,
A and B). Subsequently, the two siRNAs were added to
HLMVEC freshly plated on ECIS arrays. TER was moni-
tored starting 24 h later, and, for comparison purposes, data
are presented normalized to the 24-h values. Over the next
20 h HLMVEC lacking most of HDAC3 and -6 exhibited
faster proliferation (Fig. 7C). At 48 h postplating, LPS (1
EU/ml) was added to the arrays, and, for comparison pur-
poses, TER data were again normalized to the value just
before LPS addition. Cells lacking HDAC3 and -6 were
significantly more resistant to LPS than cells transfected
with scrambled siRNA (Fig. 7D).
Combined inhibition of HDAC3 and -6 attenuates LPS-
mediated ALI. To investigate whether the EBD-protective
effects of HDAC3 and -6 inhibitors conferred similar protec-
tion against LPS-induced ALI, mice were injected intraperito-
neally with 10 mg/kg each of RGFP-966 and tubastatin. After
24 h, 1.5 mg/kg LPS were given intratracheally to mice under
anesthesia, and BALF was collected 24 h post-LPS instillation.
Cellular infiltration into alveoli was quantified by the counting
number of cells in BALF. LPS induced a profound and signif-
icant increase in leukocyte infiltration compared with vehicle
treatment; however, BALF from mice pretreated with RGFP-
966 and tubastatin exhibited significantly less cellular infiltra-
tion (Fig. 8A). Similarly, a partial but significant attenuation of
BALF protein concentration was observed in mice pretreated
with RGFP-966 and tubastatin compared with mice treated
with LPS (Fig. 8B). Histological examination of lung tissue
stained with hematoxylin and eosin revealed significant pro-
tection in lungs of mice treated with RGFP-966 and tubastatin
from the LPS-induced structural changes, reflected in septal
thickness and cellular infiltration (Fig. 8C), whereas MPO
staining demonstrated the granulocytic nature of the invading
cells (Fig. 8D). When quantified with respect to lung injury
index (42), the combination of HDAC3 and -6 inhibitor treat-
ment effectively protected against LPS-induced lung pathology
(Fig. 8E). Together, data in Fig. 8 indicate that combined

















































Fig. 7. Small-interfering RNA (siRNA)-in-
duced downregulation of both HDAC3 and
HDAC6 protects against LPS-induced EBD.
A and B: HLMVEC were transfected with
either scrambled siRNA or siRNAs against
both HDAC3 and -6. Later (48 h) transfected
cells were lysed and immunoblotted with
antibodies against HDAC3 (A) and HDAC6
(B). *P  0.05 and ***P  0.001; n  4. C:
HLMVEC were transfected with either
scrambled siRNA or siRNAs against both
HDAC3 and -6. Later (24 h) transfected cells
were added to ECIS arrays (8W10E) and
allowed to grow to confluence. *P  0.01
from scrambled siRNA; n  4. D: the same
cells and arrays as in C. Following 24 h
exposure to siRNA, TER was normalized and
is presented as time  0. The cells were then
treated with either vehicle (PBS) or LPS (1
EU/ml) as indicated, and TER values were
monitored. P  0.05 from vehicle (*) and
LPS (#); n  4.
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DISCUSSION
Lysine acetylation is fine-tuned by the opposing actions
of two families of enzymes, histone acetyltransferases
(HAT) and HDAC. The HAT adds an acetyl group, whereas
HDAC removes acetyl groups from the ε-amino group of
lysine residues (11, 61). In humans, there are 18 character-
ized HDAC, which are distributed in four classes based on
function and DNA sequence similarity (20). Despite their
name, HDAC target not only histone but also many non-
histone proteins both in the nucleus and the cytoplasm and
regulate a variety of functions, including transcription, cy-
toskeletal polymerization, and signaling pathways (28, 30,
51, 61).
Inhibition of HDAC activity exhibits immunosuppressive
and anti-inflammatory properties by reducing cytokine produc-
tion in both humans and mice (6, 22, 30, 59). HDAC inhibition
also reduces disease severity in several animal models of
inflammatory and autoimmune diseases (6, 43, 48). In endo-
thelial cells, HDAC inhibitors have been shown to suppress
thrombin-induced EBD (49). We now show that pharmacolog-
ical and genetic inhibition of HDAC protects HLMVEC from
LPS-mediated EBD.
We have demonstrated that LPS activates Hsp90 chaperone
function by inducing Y-300 phosphorylation and that it pro-
motes EBD in cultured HLMVEC (9, 26, 36). On the other
hand, inhibition of Hsp90 prevents Y-300 phosphorylation,
attenuates chaperone function, and protects against LPS-in-
duced EBD in cultured HLMVEC. Furthermore, Hsp90 inhib-
itors prolong survival, attenuate inflammation, and reduce lung
injury in a murine model of LPS-induced ALI (15). Hsp90
chaperone function is also regulated by reversible acetylation
at residue K294. Acetylation suppresses whereas deacetylation
promotes Hsp90 chaperone function (50). HDAC inhibitors
abrogate deacetylation of Hsp90, resulting in the accumulation
of acetylated Hsp90. Because we have previously shown that
Hsp90 promotes EBD and ALI/ARDS (4, 16, 40), in this
project we determined the role of HDAC in LPS-mediated
EBD in cultured HLMVEC. We hypothesized and demon-
strated that LPS-induced HDAC activity functions upstream of


























































Fig. 8. Combined pharmacological inhibition of
HDAC3 and -6 protects against LPS-mediated
acute lung injury (ALI). Mice were injected ip
with 10 mg/kg each of RGFP-966 and tubasta-
tin. After 24 h, 1.5 mg/kg LPS were given it,
and bronchoalveolar lavage fluid (BALF) was
collected 24 h later. A: cellular infiltration into
the alveolar spaces was quantified by counting
the no. of cells in BALF. P  0.05 from vehicle
(*) and LPS (#); n  7. B: capillary permeabil-
ity was estimated by measuring protein concen-
tration in BALF using the bicinchonic acid
method. P  0.05 from vehicle (*), LPS (#), and
RT ($); n  7. Histological evaluation of lung
samples from treated mice was also performed.
C and D: sections were stained with hematox-
ylin and eosin (C) or immunocytostained
against the granulocyte marker myeloperoxi-
dase (MPO, D). Arrows point to thickened septa
and cellular infiltrates. Representative samples
of 3 specimens/group. E: estimation of lung
injury index as described previously (42). P 
0.05 from vehicle (*) and LPS (#); n  4.
L1416 HDAC-HSP90 INTERACTIONS IN ENDOTHELIAL HYPERPERMEABILITY AND ALI
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00180.2015 • www.ajplung.org
Downloaded from www.physiology.org/journal/ajplung by ${individualUser.givenNames} ${individualUser.surname} (128.082.253.035) on March 30, 2018.
Copyright © 2015 American Physiological Society. All rights reserved.
erone function. We also found that inhibition of HDAC activity
blocked LPS-induced Y-300 phosphorylation of Hsp90, sug-
gesting that HDAC inhibition also attenuates LPS-mediated
and Src-dependent phosphorylation and activation of Hsp90
(9). Thus we propose that prevention of EBD by HDAC
inhibitors is achieved by disrupting Hsp90 chaperone function.
This is supported by directly demonstrating that HDAC inhi-
bition prevents LPS-induced Akt phosphorylation (Fig. 2D).
Akt is a Hsp90 client protein, and its activation (phosphoryla-
tion) by LPS (58) or other agonists is Hsp90 dependent.
The Rho-ROCK pathway modulates cell-cell adhesion and
vascular permeability by regulating myosin-mediated contrac-
tile forces (13, 25). LPS-induced RhoA activity requires acti-
vation of Src, an Hsp90 client protein. Induction of RhoA
activity phosphorylates ROCK, which in turn phosphorylates
MLC, leading to an increase in myosin-mediated contractile
forces and EBD (1, 25). In HLMVEC, two ROCK inhibitors,
Y-27632 and GSK-429286, block MLC phosphorylation and
provide significant protection against the LPS-mediated de-
crease in TER (31). Also, inhibition of Src or Hsp90 com-
pletely abolished the LPS-induced RhoA activity and MLC
phosphorylation in HLMVEC (31). Because HDAC inhibition
suppresses Hsp90 function, we hypothesized and demonstrated
that treatment with HDAC inhibitor should also attenuate
RhoA activity and MLC phosphorylation. We also demon-
strated that, among HDACs, HDAC3 and HDAC6 are major
contributors to the LPS-induced EBD and ALI.
HDAC3, a class I HDAC, is primarily a nuclear protein that
regulates transcription (60). Phosphorylation at serine-424 in-
creases HDAC3 activity and translocates HDAC3 to the cyto-
plasm where it interacts with and deacetylates Hsp90 and
promotes its chaperone function (62). Cytoplasmic HDAC3 is
a substrate of, and regulated by, Src and has been shown to
localize at the plasma membrane (39). Consistent with these
observations, our data demonstrate that LPS selectively in-
duces HDAC3 activity by inducing serine-424 phosphorylation
and that selective inhibition of HDAC3 protects against the
LPS-induced decrease in TER, indicating that HDAC3 activity
plays a crucial role in LPS-mediated EBD.
Recently, the HDAC6-specific inhibitor tubacin was shown
to suppress thrombin-induced EBD in human pulmonary arte-
rial cells (49). HDAC6 is a unique member of class II because
it contains two homologous fully functional catalytic domains.
The COOH-terminal catalytic domain of HDAC6 possesses
-tubulin deacetylase activity and regulates microtubule dy-
namics (12, 27). HDAC6 is primarily cytoplasmic and interacts
with and deacetylates Hsp90 (5, 35). The HAT p300 acetylates
HDAC6, promotes nuclear translocation, and regulates gene
expression (38). Our data demonstrate that LPS does not
induce HDAC6 activity (data not shown); however, selective
pharmacological or genetic inhibition of HDAC6 protects
against the LPS-induced decrease in TER. This suggests that
basal HDAC6 activity is critical in inducing LPS-mediated
EBD and that inhibition of HDAC6 provides a possible strat-
egy to protect against LPS-mediated EBD.
Both HDAC3 and HDAC6 are involved in gene expression,
protein function, kinase signaling, and cytoskeletal changes in
endothelial cells (2, 32–34, 41, 49, 52, 63). In the cytoplasm,
both HDAC3 and HDAC6 interact with the molecular chaper-
one Hsp90 and regulate its chaperone activity (47). Therefore,
we speculated that combined inhibition of HDAC3 and -6
might provide better protection against LPS-mediated EBD.
Our data demonstrate that combined pharmacological or ge-
netic inhibition of HDAC3 and -6 provides significant protec-
tion against LPS-mediated EBD in HLMVEC and against
LPS-induced ALI in mice.
Binding of LPS to the endothelial cells elicits a broad
cellular response, including induction of kinase signaling path-
ways, production of proinflammatory cytokines, cytoskeletal
remodeling, and loss of cell-cell adhesion. Together these
effects cause an increase in transendothelial permeability and
lead to EBD and ALI. Hsp90 regulates the stability and activity
of many proteins in these pathways. Our present data uncover
a novel mechanism of LPS-induced endothelial hyperperme-
ability (Fig. 9). We have recently demonstrated that src and
Hsp90 interact in HLMVEC, resulting in mutually augmented
activities, of kinase and chaperone functions, respectively. We
now demonstrate that HDAC, specifically HDAC3 and
HDAC6, are also involved. At minimum, the threesome of src,
HDAC, and Hsp90 promotes enhancement of Hsp90 chaper-
one function triggered by LPS and possibly other inflammatory
molecules and are thus critically important in the development
of EBD and ALI. Consequently, the anti-inflammatory and
endothelial barrier-protective effect of HDAC and Hsp90 in-
hibitors could be exploited to treat vascular diseases with
minimal side effects.
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Fig. 9. Proposed scheme for the role of HDAC3 and -6 in LPS-mediated EBD.
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